Dan Hinmon, MCSMN Director

Posts: 2889
Joined: Apr 13, 2011

FDA Rebukes Kim Kardashian for Morning-Sickness Drug Ad on Instagram

Posted by @DanHinmon, Aug 12, 2015

The Food and Drug Administration has issued a warning letter informing Kim Kardashian’s ad partner—the morning-sickness medication Diclegis—that her Instagram post promoting the drug was a no-no. “The social media post is misleading because it presents various efficacy claims for Diclegis, but fails to communicate any risk information,” the FDA wrote to the 34-year-old reality TV star.

Any lessons here for us?


Slightly different topic, but this is a good example of why IRB offices are so adamant about reviewing clinical trial ads and social media efforts…

Was Diclegis actually behind the Kardashian post or did she do that on her own? The article is unclear.

I wondered the same about the official connection between Kardashian and Diclegis. Doing a bit more research, here’s a Kardashian quote from another article: “Duchesnay connected with me after I’d been taking Diclegis for some time. Since I had such good results, I wanted to work with Duchesnay to tell other pregnant women that Diclegis is a safe and effective option to treat morning sickness symptoms.” Sounds like money changing hands to me. http://www.breitbart.com/big-hollywood/2015/07/22/kim-kardashian-does-paid-promotion-for-controversial-morning-sickness-pill/

Liked by Megan Rowe

Please login or register to post a reply.

© Mayo Clinic Social Media Network. All Rights Reserved.